  | Hollevoet, K., Nackaerts, K., Gosselin, R., De Wever, W., BOSQUEE, L., De Vuyst, P., Germonpré, P., Kellen, E., Legrand, C., Kishi, Y., Delanghe, J. R., & Van Meerbeeck, J. P. (November 2011). Soluble Mesothelin, Megakaryocyte Potentiating Factor and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma. Journal of Thoracic Oncology, 6 (11), 1930-1937. doi:10.1097/JTO.0b013e3182272294  Peer Reviewed verified by ORBi |
 | Hollevoet, K., Van Cleemput, J., Thimpont, J., De Vuyst, P., BOSQUEE, L., Nackaerts, K., Germonpré, P., Vansteelandt, S., Kishi, Y., Delanghe, J. R., & Van Meerbeeck, J. (May 2011). Serial Measurements of Mesothelioma Serum Biomarkers in Asbestos-Exposed Individuals. Journal of Thoracic Oncology, 6 (5). doi:10.1097/JTO.0b013e31820db377 Peer Reviewed verified by ORBi |
  | BOSQUEE, L. (2011). Importance des inhibiteurs de la thyrosine kinase. Vaisseaux, Coeur, Poumons. |
 | Thonnard, A.-S., BOSQUEE, L., & CORHAY, J.-L. (2011). Le cas clinique du mois. Cancer bronchique avance non a petites cellules avec reponse exceptionnelle aux therapies ciblees. Revue Médicale de Liège, 66 (3), 121-5. Peer reviewed |
 | Hollevoet, K., Thimpont, J., Germonpré, P., BOSQUEE, L., De Vuyst, P., Legrand, C., Kellen, E., Kishi, Y., Delanghe, J. R., & Van Meerbeeck, J. P. (2010). Diagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma. American Journal of Respiratory and Critical Care Medicine, 181, 620-625. doi:10.1164/rccm.200907-1020OC Peer Reviewed verified by ORBi |
 | Nepper, S., Frusch, N., Louis, R., Ghaye, B., de Leval, L., & BOSQUEE, L. (2010). Pneumopathies organisées: à propos de 3 cas. Revue Médicale de Liège, 65 (10), 549-55. Peer reviewed |
 | Bosquee, L. (2010). Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC) [Poster presentation]. 2010 ASCO - Annual Meeting, Chicago, United States. |
 | Bosquee, L. (August 2009). Niet-kleincellige longkanker : classificatie van de "International Association for Study of Lung Cancer" (IASLC) 2007. Tempo Médical, 314, 23-26. |
 | Valdes Socin, H. G., Niaourou, V., Vandeva, S., Bosquee, L., & Beckers, A. (2009). Syndromes paranéoplasiques endocriniens: diagnostic et prise en charge. Revue Médicale Suisse, 5 (214), 1668-74. Peer Reviewed verified by ORBi |
 | Zatloukal, P., Gervais, R., Vansteenkiste, J., Bosquee, L., Sessa, C., Brain, E., Dansin, E., Urban, T., Dohollou, N., Besenval, M., & Quoix, E. (August 2008). Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer. Journal of Thoracic Oncology, 3 (8), 894-901. doi:10.1097/JTO.0b013e31817e6669 Peer Reviewed verified by ORBi |
 | Allan, S., BOSQUEE, L., Franke, A., Pirker, R., & Scagliotti, G. (May 2008). Efficacy of Erlotinib in patients (PTS) with advanced non-small-cell lung cancer (NSCLC) relative to clinical charesteristics : subset analyses from the trust study. American Journal of Clinical Oncology, 26 (20). Peer Reviewed verified by ORBi |
 | Coucke, P., Barthelemy, N., Bosquee, L., & Van Meerbeeck. (2008). Is an evidence-based approach unrealistic in NSCLC? Belgian Journal of Medical Oncology, volume 2 (6), 326-333. Peer Reviewed verified by ORBi |
 | Bosquee, L., Frusch, N., & Louis, R. (29 August 2007). Prise en charge du cancer pulmonaire non a petites cellules. Revue Médicale Suisse, 3 (122), 1890-5. |
 | Kim, E. S., & Bosquee, L. (June 2007). The importance of accurate lymph node staging in early and locally advanced non-small cell lung cancer: An update on available techniques. Journal of Thoracic Oncology, 2 (6, Suppl. S), 59-S67. doi:10.1097/01.JTO.0000269738.13586.fd Peer Reviewed verified by ORBi |
 | Talbot, D. C., von Pawel, J., Cattell, E., Yule, S. M., Johnston, C., Zandvliet, A. S., Huitema, A. D. R., Norbury, C. J., Ellis, P., Bosquee, L., & Reck, M. (15 March 2007). A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Clinical Cancer Research, 13 (6), 1816-1822. doi:10.1158/1078-0432.CCR-06-0249 Peer Reviewed verified by ORBi |
 | van Puijenbroek, R., Bosquee, L., Meert, A. P., Schallier, D., Goeminne, J. C., Tits, G., Collard, P., Nackaerts, K., Canon, J. L., Duplaquet, F., Galdermans, D., Germonpré, P., Azerad, M.-A., Vandenhoven, G., De Greve, J., & Vansteenkiste, J. (January 2007). Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study. European Respiratory Journal, 29 (1), 128-33. doi:10.1183/09031936.00050706 Peer Reviewed verified by ORBi |
 | Louis, R., Bosquee, L., DUYSINX, B., & Corhay, J.-L. (2007). Actualites therapeutiques en pneumologie. Revue Médicale de Liège, 62 (5-6, May-Jun), 288-92. Peer reviewed |
 | Frusch, N., Bosquee, L., & Louis, R. (2007). Le cancer du poumon. Epidemiologie et facteurs etiologiques. Revue Médicale de Liège, 62 (9), 548-53. Peer reviewed |
 | Barthelemy, N., Rinken, F., Dekoster, G., & Bosquee, L. (November 2006). Efficacy and Morbidity of a Novel Induction Treatment in Locally Advanced Non Small Cell Lung Cancer (NSCLC). International Journal of Radiation, Oncology, Biology, Physics, 66 (3), 476-S477. doi:10.1016/j.ijrobp.2006.07.890 Peer Reviewed verified by ORBi |
 | Scagliotti, G. V., Smit, E., Bosquee, L., O'Brien, M., Ardizzoni, A., Zatloukal, P., Eberhardt, W., Smid-Geirnaerdt, M., de Bruin, H. G., Dussenne, S., Legrand, C., & Giaccone, G. (October 2005). A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung Cancer, 50 (1), 91-96. doi:10.1016/j.lungcan.2005.05.012 Peer Reviewed verified by ORBi |
 | Schleich, F., Bustin, F., Bosquee, L., & Legros, J.-J. (September 2005). Diabete insipide dans le cadre d'un carcinome pulmonaire a petites cellules: un paradoxe? Annales d'Endocrinologie, 66 (4), 355-60. doi:10.1016/S0003-4266(05)81793-7 Peer Reviewed verified by ORBi |
 | Bosquee, L., Rinken, F., Bustin, F., Gustin, M., Broux, R., Angelescu, S., Dekoster, G., & Barthelemy, N. (July 2005). Efficacy and morbidity of a novel induction treatment for locally advanced NSCLC. Lung Cancer, 49 (Suppl. 2), 78. doi:10.1016/S0169-5002(05)80373-3 Peer Reviewed verified by ORBi |
 | van Puijenbroek, R., Bosquee, L., Tits, G., Germonpre, P., Strobbe, E., & Vansteenkiste, J. (July 2005). Experience from a large multi-centre expanded access programme (EAP) with gefitinib ('Iressa', ZD1839) as monotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer, 49 (Suppl. 2), 273. Peer Reviewed verified by ORBi |
 | Barthelemy, N., Bosquee, L., & Quaedvlieg, V. (August 2003). Phase II trial exploring gemcitabine and cisplatin as treatment of patients with non-small cell lung cancer (NSCLC) and inoperable brain metastases. Lung Cancer, 41 (supp2), 145. Peer Reviewed verified by ORBi |
 | Barthelemy, N., Bosquee, L., Bartsch, P., Deneufbourg, J.-M., Albert, A., & Nusgens, B. (August 2003). Interleukin-6 and transforming growth factor-beta1 are increased in bronchoalveolar lavage fluid following thoracic radiotherapy. Lung Cancer, 41 (supp2), 173. Peer Reviewed verified by ORBi |
 | Vansteenkiste, J., Vandebroek, J., Nackaerts, K., Dooms, C., Galdermans, D., Bosquee, L., Delobbe, A., Deschepper, K., Van Kerckhoven, W., Vandeurzen, K., Deman, R., D'Odemont, J. P., Siemons, L., Van den Brande, P., & Dams, N. (May 2003). Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine. Lung Cancer, 40 (2), 191-199. doi:10.1016/S0169-5002(02)00515-9 Peer Reviewed verified by ORBi |
 | Mommens, V., Bosquee, L., & D'Orio, V. (March 2003). Toxicite pulmonaire de la gemcitabine dans le cadre d'un CPNPC avec carcinomatose cerebrale. Revue Médicale de Liège, 58 (3), 123-6. Peer reviewed |
 | Ardizzoni, A., Manegold, C., Debruyne, C., Gaafar, R., Buchholz, E., Smit, E. F., Lianes, P., ten Velde, G., Bosquee, L., Legrand, C., Neumaier, C., King, K., & Giaccone, G. (January 2003). European Organization for Research and Treatment of Cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clinical Cancer Research, 9 (1), 143-150. Peer Reviewed verified by ORBi |
 | Barthelemy, N., David, J.-L., Bosquee, L., Bury, T., Seidel, L., Albert, A., Bartsch, P., BAUGNET-MAHIEU, L., & Deneufbourg, J.-M. (March 2002). Increased TGFβ1 plasma level in patients with lung cancer: potential mechanisms. European Journal of Clinical Investigation, 32 (3), 193-198. doi:10.1046/j.1365-2362.2002.00956.x Peer Reviewed verified by ORBi |
 | Sautois, B., Fraipont, V., Baudoux, E., Fassotte, M.-F., Hermanne, J. P., Jerusalem, G., Bours, V., Bosquee, L., Schaaf-Lafontaine, N., Paulus, J.-M., Sondag, D., Fillet, G., & Beguin, Y. (1999). Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. Haematologica, 84 (4), 342-9. Peer Reviewed verified by ORBi |
 | Barthelemy, N., Bosquee, L., Baugnet, Bartsch, P., & Deneufbourg, J.-M. (1997). Pulmonary function changes in patients with lung cancer treated by combined radiation and chemotherapy. Lung Cancer. Peer Reviewed verified by ORBi |